Topical, early weeks
Trial endpoints were assessed over 8–12 weeks rather than days.
Protocol / Research Dosing Guide
GHK-Cu Dosage Guide: Topical Evidence, Injectable Reports and Safety
An evidence-organized GHK-Cu guide that keeps the published topical human evidence separate from the reported injectable practice, so the stronger and weaker parts of the record stay visible.
Last reviewed September 15, 202618 minute readResearch information only
Level 3 — Human topical evidenceInjectable use is reported, not trialedNot FDA approved
GHK-Cu Quick Start
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, with levels declining substantially with age. The strongest human evidence is topical, including a controlled facial photoaging trial. Injectable use is widely discussed but has no published human randomized trial.
Why researchers care
Skin, hair, and wound-healing research
Class
Copper-binding tripeptide, glycyl-L-histidyl-L-lysine copper complex
Route reported
Topical formulations carry the human evidence; subcutaneous use is community reported
Cycle length
Reported injectable cycles of 4–8 weeks; not trial validated
Regulatory status
Not FDA approved as a drug; copper tripeptide-1 is an established cosmetic ingredient
Loading supplier information
GHK-Cu Dosing Protocol and Schedule
The supplied coverage source separates two formats. For topical use it cites 1–3 percent formulations applied once or twice daily over 8–12 weeks. For injectable use it describes a reported 1–2 mg daily subcutaneous range across 4–8 week cycles, explicitly labeled as community-derived planning rather than a recommendation.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Reported injectable, conservative | 1.0 mg daily subcutaneous | 5 days on, 2 off, for about 4 weeks |
| Reported injectable, standard | 1.0–1.5 mg daily subcutaneous | Daily for 4–6 weeks |
| Reported injectable, higher end | 1.5–2.0 mg daily subcutaneous | Daily for 6–8 weeks |
| Topical, facial | 1–2 percent formulation | Once or twice daily for 8–12 weeks |
| Topical, scalp | 1–3 percent formulation | Daily, ongoing in reported use |
No human randomized trial has established an injectable amount, frequency, cycle length, or rest period. Reported 2–4 week breaks between injectable cycles are community-derived. Topical percentages come from cosmetic and compounded formulations, with the 12-week facial trial as the anchor.
GHK-Cu Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
GHK-Cu Reconstitution Calculator
Vial-format concentration math
Concentration
25 mg/mL
Draw volume
0.04 mL
U-100 units
4
Mathematical draws
50
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take GHK-Cu: Morning or Night?
Morning or evening?
Not established for either format. Topical trials used once- or twice-daily application without a timing comparison.
Once or twice daily?
Topical trial protocols used once or twice daily. Reported injectable use is once daily.
With food?
Not applicable to topical or injected formats.
Missed application or amount?
No validated replacement procedure exists.
GHK-Cu Route Comparison
| Route | What is reported | Evidence limit |
|---|---|---|
| Topical | Controlled human facial and skin studies | Cosmetic and skin endpoints only |
| Subcutaneous | Reported community cycles of 1–2 mg daily | No published human randomized trial |
| Microneedling-adjacent | Compounded post-procedure use | Per clinician practice, not trial evidence |
| Route conversion | None available | Percent-by-weight topical strengths and injected milligrams are not comparable |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
GHK-Cu Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life of injected GHK-Cu | Not established | No published human PK study for the injected format |
| Plasma presence | GHK occurs naturally in plasma and declines with age | Endogenous levels are not a dosing basis |
| Topical residence | Not established | Skin-penetration kinetics are formulation dependent |
| Frequency rationale | Daily use is reported | Not validated against alternatives |
GHK-Cu Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 1.0 mg | Once daily | Community report | No |
| Subcutaneous | 1.5 mg | Once daily | Community report | No |
| Subcutaneous | 2.0 mg | Once daily | Community report | No |
| Topical | 1–2 percent | Once or twice daily | Human trial and cosmetic practice | No |
| Topical | 3 percent and above | Daily | Compounded practice | No; irritation reports increase |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
GHK-Cu Reconstitution Guide
Concentration: 25 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 1 mg | 0.04 mL | 4 units |
| 2 mg | 0.08 mL | 8 units |
| 3 mg | 0.12 mL | 12 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How GHK-Cu Works
Copper transport
GHK binds copper with high affinity and is studied as a copper-delivery molecule for skin and repair processes.
GHK-Cu Human Trials and FDA Status
Current status · verified September 15, 2026
Not FDA approved as a drug; copper tripeptide-1 is an established cosmetic ingredient
- A controlled facial photoaging trial reported skin improvements with a topical copper-peptide cream over 12 weeks.
- A small topical gel study in women reported increased skin collagen density at three months.
- Extensive review literature describes wound-healing and skin-remodeling research, largely preclinical and topical.
- No published human randomized trial has evaluated injectable GHK-Cu for skin, hair, or wound endpoints.
- GHK-Cu has no FDA-approved drug indication; copper tripeptide-1 is used as a cosmetic ingredient.
Who Should Avoid GHK-Cu?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data for injected use
Wilson disease or copper-metabolism disorders
The compound delivers copper
Known copper sensitivity
Copper reactions are documented
Active or prior cancer
Angiogenesis-related questions are unresolved
Concurrent medicines
No interaction studies for injected use
Broken or inflamed skin with high-percentage topicals
Irritation reports increase with concentration
GHK-Cu Side Effects, Risks and Safety
Skin irritation or redness with topical useReported
Important limitation: Increases at higher formulation percentages.
Injection-site irritationReported
Important limitation: No controlled incidence data.
Copper accumulation concernsTheoretical
Important limitation: No injected-format monitoring data.
Allergic responseReported for copper exposure generally
Important limitation: No compound-specific incidence data.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term injectable safetyUnknown
Important limitation: No long-term follow-up.
GHK-Cu Timeline and Monitoring
Topical, three months
Collagen-density findings in the small gel study were measured at three months.
Injectable
No validated onset, peak, or duration exists.
Monitoring
No required panel is established. Copper status testing is sometimes discussed but is not a validated protocol marker.
GHK-Cu Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Facial skin appearance | Human topical evidence | Controlled photoaging trial | Cosmetic endpoints, topical format only |
| Collagen density | Limited human topical evidence | Small three-month gel study | Twenty-one participants |
| Wound healing | Preclinical and review evidence | Animal and laboratory work | No controlled human injectable trial |
| Hair research interest | Not established | Community practice and cosmetic use | No adequate controlled trial |
GHK-Cu Storage and Handling
Unreconstituted vial
Follow the exact product label; keep dry and away from light.
Prepared vial
Reported handling refrigerates the solution; no validated stability study for a reconstituted research vial was located.
Color
GHK-Cu solutions are characteristically blue from the copper complex; color alone does not confirm purity or sterility.
Topical products
Follow the specific product label; formulation stability varies by base.
GHK-Cu Troubleshooting
Percent strength confused with milligrams
A one percent topical is roughly 10 mg per gram of finished product; it is not an injected amount.
Units do not match another chart
Recheck vial milligrams, liquid volume, entered amount, and the U-100 conversion.
Topical evidence quoted for injection
The controlled human evidence is topical and does not validate injected use.
Irritation with a high-percentage topical
Irritation reports rise with concentration; formulation choices belong with a clinician.
Vial size differs from the chart
A 50 mg and a 100 mg vial need different liquid volumes for the same concentration.
GHK-Cu Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| GHK-Cu | Copper tripeptide | Human topical trials; no injectable trial | Cosmetic ingredient, not an approved drug |
| Matrixyl (palmitoyl pentapeptide) | Cosmetic signal peptide | Cosmetic formulation studies | Cosmetic ingredient |
| Retinoids | Vitamin A derivatives | Extensive controlled dermatology evidence | Approved drugs and cosmetic products |
| BPC-157 | Repair-signaling peptide | Mostly animal evidence | Not approved |
GHK-Cu Frequently Asked Questions
What is GHK-Cu?
A copper-binding tripeptide, glycyl-L-histidyl-L-lysine bound to copper, that occurs naturally in human plasma.
Which route has the best evidence?
Topical. The controlled human studies used creams or gels, not injections.
Is injectable GHK-Cu studied in humans?
No published human randomized trial was identified for the injectable format.
What amounts are reported for injection?
Community references describe 1–2 mg daily over 4–8 week cycles. That is reported practice, not a validated schedule.
What topical strengths are used?
Cosmetic and compounded products commonly range from 1 to 3 percent; irritation reports rise at higher strengths.
Why is the solution blue?
The copper complex gives the solution its characteristic color. Color does not confirm purity or sterility.
What is its half-life?
Not established for the injected format.
Is it FDA approved?
Not as a drug. Copper tripeptide-1 is an established cosmetic ingredient.
Who should be cautious?
Anyone with a copper-metabolism disorder, copper sensitivity, or a cancer history, and anyone pregnant or breastfeeding.
What does the calculator do?
It converts entered vial and liquid values into concentration, draw volume, and U-100 unit arithmetic only.
Sources and Research
Coverage source
1. GHK-Cu protocol coverage source
Supplied coverage source for reported injectable and topical patterns and information categories; not primary evidence.
Open direct sourceHuman research
2. Skin care benefits of copper peptide containing facial cream (Leyden et al., photoaging study)
Controlled human topical study anchoring the facial skin evidence.
Open direct sourceReview
3. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration
Peer-reviewed review of GHK biology, copper binding, and age-related plasma decline.
Open direct sourceMissing information flagged for review
- Human randomized trial of injectable GHK-Cu: Not established
- Injected-format pharmacokinetics and half-life: Not established
- Validated injectable amount, cycle, and rest period: Not established
- Copper-load monitoring guidance for injected use: Not established
- Adequate controlled hair-research evidence: Not established
- Long-term safety data: Not established